Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...
Schrödinger, Inc. (SDGR): A Bull Case Theory
We came across a bullish thesis on Schrödinger, Inc. (SDGR) on Value Degen’s Substack by Unemployed Value Degen. In this ...
How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market
Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".
The Motley Fool on MSN2h
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
The early trial of TERN-601 is encouraging, but I wouldn't buy shares of the stock just yet. It's still far too early in the ...
Zacks.com on MSN21h
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...
Business Insider India11h
The CEO of pharma giant Eli Lilly shares 3 ways AI could transform his industry
Eli Lilly has a market value of more than $420 billion, and sells blockbuster treatments for diabetes and cancer. It's already begun to invest in a host of projects focused on AI. A spokesperson ...